Abeona Therapeutics Inc (ABEO)
4.60
+0.53
(+13.02%)
USD |
NASDAQ |
May 03, 16:00
4.61
+0.01
(+0.22%)
After-Hours: 20:00
Abeona Therapeutics Cash from Financing (TTM): 37.06M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 37.06M |
September 30, 2023 | 72.36M |
June 30, 2023 | 53.57M |
March 31, 2023 | 43.17M |
December 31, 2022 | 43.17M |
September 30, 2022 | 16.74M |
June 30, 2022 | 12.72M |
March 31, 2022 | 18.98M |
December 31, 2021 | 24.86M |
September 30, 2021 | 8.533M |
June 30, 2021 | 8.36M |
March 31, 2021 | 7.814M |
December 31, 2020 | 1.936M |
September 30, 2020 | 98.46M |
June 30, 2020 | 102.80M |
March 31, 2020 | 113.87M |
December 31, 2019 | 113.90M |
September 30, 2019 | 17.37M |
June 30, 2019 | 16.11M |
March 31, 2019 | 3.676M |
December 31, 2018 | 5.477M |
September 30, 2018 | 92.74M |
June 30, 2018 | 94.72M |
March 31, 2018 | 94.23M |
December 31, 2017 | 92.40M |
Date | Value |
---|---|
September 30, 2017 | 46.51M |
June 30, 2017 | 42.47M |
March 31, 2017 | 42.54M |
December 31, 2016 | 42.54M |
September 30, 2016 | 1.169M |
June 30, 2016 | 15.56M |
March 31, 2016 | 36.05M |
December 31, 2015 | 35.65M |
September 30, 2015 | 48.11M |
June 30, 2015 | 32.95M |
March 31, 2015 | 12.31M |
December 31, 2014 | 12.71M |
September 30, 2014 | 0.25M |
June 30, 2014 | 0.018M |
March 31, 2014 | 0.029M |
December 31, 2013 | |
September 30, 2013 | |
June 30, 2013 | |
March 31, 2013 | |
December 31, 2012 | |
September 30, 2012 | |
June 30, 2012 | |
March 31, 2012 | |
December 31, 2011 | 3.076M |
September 30, 2011 | 7.253M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
1.936M
Minimum
Dec 2020
113.90M
Maximum
Dec 2019
42.73M
Average
24.86M
Median
Dec 2021
Cash from Financing (TTM) Benchmarks
T2 Biosystems Inc | 52.69M |
INVO Bioscience Inc | 7.392M |
Perspective Therapeutics Inc | 0.785M |
Electromed Inc | -0.128M |
Xtant Medical Holdings Inc | 19.69M |